| Not Yet Recruiting | Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones NCT06982222 | National Cancer Institute (NCI) | Phase 1 |
| Not Yet Recruiting | Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-S NCT06816979 | Ohio State University Comprehensive Cancer Center | N/A |
| Not Yet Recruiting | Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment NCT07393555 | SWOG Cancer Research Network | Phase 2 |
| Recruiting | Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non- NCT07012031 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Not Yet Recruiting | SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer NCT07322341 | University of Washington | Phase 2 |
| Not Yet Recruiting | Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic St NCT06943664 | Roswell Park Cancer Institute | Phase 2 |
| Recruiting | Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-lin NCT07288034 | City of Hope Medical Center | Phase 2 |
| Recruiting | GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cel NCT07017829 | Roswell Park Cancer Institute | Phase 2 |
| Not Yet Recruiting | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tum NCT07405086 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cance NCT06616584 | SWOG Cancer Research Network | Phase 2 / Phase 3 |
| Recruiting | Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non- NCT06910761 | City of Hope Medical Center | Phase 2 |
| Withdrawn | Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer NCT05840770 | City of Hope Medical Center | Phase 2 |
| Recruiting | Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunother NCT06731270 | Emory University | Phase 2 |
| Recruiting | Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Dur NCT06287775 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis NCT06500481 | NRG Oncology | Phase 3 |
| Recruiting | Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast C NCT06518057 | University of Washington | Phase 2 |
| Recruiting | Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer NCT06616623 | Dwight Owen | Phase 1 |
| Recruiting | Novel INPUT Screening Tool to Improve Illness Understanding in Patients With Metastatic or Incurable Lung Canc NCT06743308 | M.D. Anderson Cancer Center | N/A |
| Recruiting | Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has NCT06500455 | NRG Oncology | Phase 3 |
| Recruiting | Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer NCT06660407 | Mayo Clinic | Phase 2 |
| Recruiting | Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase NCT06014827 | City of Hope Medical Center | Phase 2 |
| Recruiting | Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Exp NCT06031688 | SWOG Cancer Research Network | Phase 2 |
| Recruiting | Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small NCT06495125 | Emory University | Phase 2 |
| Recruiting | Gilteritinib for the Treatment of ALK NSCLC NCT06225427 | University of Michigan Rogel Cancer Center | Phase 1 |
| Recruiting | Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung C NCT06096844 | National Cancer Institute (NCI) | Phase 3 |
| Recruiting | Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Met NCT06249282 | City of Hope Medical Center | Phase 1 |
| Not Yet Recruiting | Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Ce NCT06067776 | Jonathan Riess | Phase 1 |
| Terminated | An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improvi NCT06315296 | Thomas Jefferson University | N/A |
| Recruiting | LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia NCT06073431 | University of Rochester | — |
| Withdrawn | OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cance NCT05935774 | University of Washington | Phase 2 |
| Recruiting | A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer NCT06122064 | Mayo Clinic | N/A |
| Withdrawn | Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive S NCT05161533 | University of Washington | Phase 2 |
| Recruiting | The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor C NCT05967533 | University of California, Davis | Phase 1 |
| Unknown | EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer NCT05498389 | Shanghai EpimAb Biotherapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lun NCT05501665 | Vanderbilt-Ingram Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Ch NCT05642572 | SWOG Cancer Research Network | Phase 2 |
| Recruiting | Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or L NCT05746325 | Mayo Clinic | N/A |
| Recruiting | SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Ca NCT05570825 | University of Washington | Phase 2 |
| Active Not Recruiting | A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer NCT05242965 | University of Washington | Phase 2 |
| Active Not Recruiting | Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer NCT05633602 | SWOG Cancer Research Network | Phase 3 |
| Recruiting | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Pati NCT05733000 | Northwestern University | Phase 2 |
| Active Not Recruiting | Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer NCT05340309 | University of Southern California | Phase 2 |
| Recruiting | PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer NCT05234307 | Dwight Owen | Phase 1 |
| Recruiting | Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer NCT05493566 | Emory University | EARLY_Phase 1 |
| Suspended | Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) NCT04929041 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Terminated | Remote Monitoring With Health-Coaching for Lifestyle Changes in Patients With Lung Cancer Related Fatigue NCT05407038 | Mayo Clinic | N/A |
| Recruiting | Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer NCT05244239 | Emory University | Phase 1 |
| Withdrawn | Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer NCT05364645 | SWOG Cancer Research Network | Phase 2 |
| Active Not Recruiting | Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small C NCT05334329 | University of California, Irvine | Phase 1 |
| Recruiting | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positiv NCT05098210 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial NCT05339022 | Ohio State University Comprehensive Cancer Center | N/A |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Active Not Recruiting | A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Can NCT05215769 | Ohio State University Comprehensive Cancer Center | N/A |
| Active Not Recruiting | Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual NCT05096663 | SWOG Cancer Research Network | Phase 2 / Phase 3 |
| Active Not Recruiting | Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer NCT05166616 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic NCT05017025 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung NCT04919382 | Dwight Owen | Phase 2 |
| Recruiting | Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lu NCT04780568 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumor NCT04514497 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lu NCT04919369 | Dwight Owen | Phase 1 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or C NCT04491942 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery NCT04588246 | NRG Oncology | Phase 3 |
| Terminated | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab NCT04639245 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Canc NCT04971187 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer NCT05045404 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids NCT04804644 | NRG Oncology | Phase 3 |
| Completed | A Biobehavioral/Cognitive Treatment for Stress, Depression, and Anxiety in Patients With Stage IV Lung Cancer NCT05342571 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | Evaluating Modifiable Biomarkers for the Prediction of Immunotherapy Response and Toxicity NCT04954885 | Ohio State University Comprehensive Cancer Center | — |
| Active Not Recruiting | Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lun NCT04625647 | SWOG Cancer Research Network | Phase 2 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin NCT04216316 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progress NCT04902040 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metasta NCT04785287 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Pos NCT04837716 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | A Nurse-Led Intervention for Fear of Progression in Advanced Cancer NCT04819997 | City of Hope Medical Center | N/A |
| Recruiting | MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer NCT04762199 | Emory University | Phase 1 |
| Recruiting | Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer NCT03819296 | M.D. Anderson Cancer Center | Phase 1 |
| Withdrawn | Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Pro NCT05022394 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases NCT04752267 | University of Southern California | EARLY_Phase 1 |
| Recruiting | Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-s NCT04751747 | Rutgers, The State University of New Jersey | N/A |
| Completed | BeWell360-CG Care Model: Health and Wellness Coaching to Support Caregivers of Patients Living With Advanced L NCT05640765 | Mayo Clinic | N/A |
| Recruiting | Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Sol NCT04771520 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases NCT04789668 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-S NCT04728230 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer NCT04181060 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 7 NCT04533451 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Active Not Recruiting | National Cancer Institute "Cancer Moonshot Biobank" NCT04314401 | National Cancer Institute (NCI) | — |
| Active Not Recruiting | Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-s NCT04250545 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer NCT04396535 | Mayo Clinic | Phase 2 |
| Withdrawn | Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous C NCT04267913 | SWOG Cancer Research Network | Phase 2 |
| Active Not Recruiting | Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis NCT04516070 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Decision Aid for the Improvement of Decision-Making in Patients With Non-small Cell Lung Cancer NCT04946279 | OHSU Knight Cancer Institute | N/A |
| Completed | Family Caregivers in Underserved Populations Providing Complex Cancer Care NCT05213078 | City of Hope Medical Center | N/A |
| Active Not Recruiting | Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared NCT04310007 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Muta NCT04479306 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Can NCT04120454 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1 NCT04340882 | Emory University | Phase 2 |
| Active Not Recruiting | Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-s NCT03965689 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) NCT04268550 | SWOG Cancer Research Network | Phase 2 |
| Withdrawn | Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer NCT04262869 | Emory University | Phase 2 |
| Active Not Recruiting | Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lun NCT03831932 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCL NCT04227028 | City of Hope Medical Center | Phase 1 |
| Completed | Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung C NCT04173507 | SWOG Cancer Research Network | Phase 2 |
| Active Not Recruiting | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors NCT04007744 | Mayo Clinic | Phase 1 |
| Completed | Resiliency Among Older Adults Receiving Lung Cancer Treatment NCT04229381 | Ohio State University Comprehensive Cancer Center | N/A |
| Active Not Recruiting | WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Centr NCT04197934 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lun NCT04073745 | Roswell Park Cancer Institute | Phase 1 |
| Suspended | Paclitaxel Therapeutic Drug Monitoring in Cancer Patients NCT03987555 | Wake Forest University Health Sciences | — |
| Withdrawn | [18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing P NCT04186988 | University of California, Davis | EARLY_Phase 1 |
| Recruiting | PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung C NCT04151940 | University of Washington | N/A |
| Terminated | Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC NCT04081688 | Rutgers, The State University of New Jersey | Phase 1 |
| Active Not Recruiting | Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study NCT04430725 | M.D. Anderson Cancer Center | — |
| Active Not Recruiting | Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell NCT03737994 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study NCT03707574 | National Cancer Institute (NCI) | — |
| Active Not Recruiting | CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell NCT03546361 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Recruiting | Insomnia in Patients With Metastatic Lung Cancer NCT06472804 | Mayo Clinic | — |
| Terminated | Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer NCT03995667 | OHSU Knight Cancer Institute | Phase 2 |
| Completed | Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-smal NCT03971474 | SWOG Cancer Research Network | Phase 2 |
| Completed | Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent NCT03845296 | SWOG Cancer Research Network | Phase 2 |
| Active Not Recruiting | Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non- NCT03793179 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell L NCT03581487 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Geriatric and Quality of Life Assessments in Older Patients With Non-metastatic or Metastatic Head and Neck or NCT03902535 | City of Hope Medical Center | — |
| Active Not Recruiting | Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage S NCT03830918 | Jonsson Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Completed | Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer NCT03944265 | Thomas Jefferson University | N/A |
| Recruiting | Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non NCT03948100 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung NCT03707938 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Embedded Palliative Care in Managing Symptoms in Participants With Recurrent Stage III-IV Thoracic Malignancie NCT04662645 | Ohio State University Comprehensive Cancer Center | N/A |
| Active Not Recruiting | Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lun NCT03600701 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer NCT03637816 | M.D. Anderson Cancer Center | Phase 2 / Phase 3 |
| Completed | Conquer Fear SUPPORT Intervention in Supporting Patients With Stage III-IV Lung or Gynecologic Cancer NCT03776253 | City of Hope Medical Center | N/A |
| Active Not Recruiting | Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small NCT03731585 | M.D. Anderson Cancer Center | N/A |
| Terminated | Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer NCT03662074 | Wake Forest University Health Sciences | Phase 2 |
| Terminated | Bronchoscopic Laser Ablation of Peripheral Lung Tumors NCT03707925 | M.D. Anderson Cancer Center | N/A |
| Completed | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies NCT03590054 | Rahul Aggarwal | Phase 1 |
| Recruiting | Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery NCT03582124 | Stanford University | Phase 1 / Phase 2 |
| Active Not Recruiting | Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and NCT02971501 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease NCT03025256 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic NCT03225664 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Can NCT03410043 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Sm NCT03391869 | M.D. Anderson Cancer Center | Phase 3 |
| Active Not Recruiting | Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment NCT02589522 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung C NCT02983578 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or NCT02955290 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Rem NCT02595931 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Ca NCT02496663 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medication NCT02595866 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherap NCT02419495 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types NCT06075524 | Mayo Clinic | — |
| Completed | 4D PET/CT in Diagnosing Participants With Lung and Colorectal Cancer With Liver and Lung Metastasis NCT00862680 | M.D. Anderson Cancer Center | — |